Westman J, Eriksson SV, Gissler M, Hällgren J, Prieto ML, Bobo WV, et al. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiol Psychiatr Sci. 2018;27(5):519–27.

Article  CAS  PubMed  Google Scholar 

Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–47.

Article  PubMed  PubMed Central  Google Scholar 

Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Borglum AD, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry. 2017;174(7):686–94.

Article  PubMed  Google Scholar 

Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–21.

Article  PubMed  Google Scholar 

Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83–8.

Article  PubMed  Google Scholar 

Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–80.

Article  PubMed  PubMed Central  Google Scholar 

Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1–3):15–22.

Article  PubMed  Google Scholar 

Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):401.

Article  PubMed  PubMed Central  Google Scholar 

Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122(1–3):1–23.

Article  PubMed  Google Scholar 

Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–71.

Article  CAS  PubMed  Google Scholar 

Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open. 2014;2(4):E225–32.

Article  Google Scholar 

Radojčić MR, Pierce M, Hope H, Senior M, Taxiarchi VP, Trefan L, et al. Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000–19 primary care data. Lancet Psychiatry. 2023;10(2):119–28.

Article  PubMed  Google Scholar 

Pringsheim T, Gorman D, Pringsheim T, Gorman D. Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review. Can J Psychiat. 2012;57(12):722–7.

Article  Google Scholar 

Pringsheim T, Lam D, Patten SB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005–2009. J Child Adolesc Psychopharmacol. 2011;21(6):537–43.

Article  PubMed  Google Scholar 

Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119–36.

Article  PubMed  PubMed Central  Google Scholar 

Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73–96.

Article  CAS  PubMed  Google Scholar 

Kowalchuk C, Castellani LN, Chintoh A, Remington G, Giacca A, Hahn MK. Antipsychotics and glucose metabolism: how brain and body collide. Am J Physiol Endocrinol Metab. 2019;316(1):E1–15.

Article  CAS  Google Scholar 

Werner FM, Coveñas R. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf. 2014;13(8):1031–42.

Article  CAS  PubMed  Google Scholar 

Vrbová K, Kamarádová D, Látalová K, Ocisková M, Praško J, Mainerová B, et al. Self-stigma and adherence to medication in patients with psychotic disorders–cross-sectional study. Neuro Endocrinol Lett. 2014;35(7):645–52.

PubMed  Google Scholar 

Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017;47(6):1030–40.

Article  CAS  PubMed  Google Scholar 

Cooper SJ, Reynolds GP, Barnes T, England E, Haddad P, Heald A, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30(8):717–48.

Article  CAS  PubMed  Google Scholar 

Simon J, Wienand D, Park AL, Wippel C, Mayer S, Heilig D, et al. Excess resource use and costs of physical comorbidities in individuals with mental health disorders: a systematic literature review and meta-analysis. Eur Neuropsychopharmacol. 2023;66:14–27.

Article  CAS  PubMed  Google Scholar 

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96.

Article  CAS  PubMed  Google Scholar 

• Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(3):295–314. A large meta-analysis demonstrating that all antipsychotics, including first-generation agents, induce significant weight gain; most also cause clinically significant weight gain ≥7%.

Article  CAS  PubMed  Google Scholar 

Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE. 2014;9(4):e94112.

Article  PubMed  PubMed Central  Google Scholar 

Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010;40(2):187–200.

Article  CAS  PubMed  Google Scholar 

•• Campforts B, Drukker M, Crins J, Van Amelsvoort T, Bak M. Association between antipsychotic medication and clinically relevant weight change: meta-analysis. BJPsych Open. 2023;9(1). This study conducted large meta-analyses and meta-regressions to better understand risk factors and moderators of clinically significant AIWG. AIWG was more pronounced in first-episode patients, individuals with schizophrenia, and longer duration of AP use.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–97.

Article  CAS  PubMed  Google Scholar 

Chang S-C, Goh KK, Lu M-L. Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: state-of-the-art and future perspectives. World J Psychiatry. 2021;11(10):696–710.

Article  PubMed  Google Scholar 

Benarroch L, Kowalchuk C, Wilson V, Teo C, Guenette M, Chintoh A, et al. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology. 2016;233(14):2629–53.

Article  CAS  PubMed  Google Scholar 

Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–41.

Article  PubMed  PubMed Central  Google Scholar 

Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain. CNS Drugs. 2011;25(12):1035–59.

Article  CAS  PubMed  Google Scholar 

Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry. 1978;135(2):165–73.

Article  CAS  Google Scholar 

Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13–23.

Article  PubMed  Google Scholar 

Nicol GE, Kolko R, Lenze EJ, Yingling MD, Miller JP, Ricchio AR, et al. Adiposity, hepatic triglyceride, and carotid intima media thickness during behavioral weight loss treatment in antipsychotic-treated youth: a randomized pilot study. J Child Adolesc Psychopharmacol. 2019;29(6):439–47.

Article  CAS  PubMed  Google Scholar 

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh R, Stogios N, Smith E, Lee J, Maksyutynsk K, Au E, et al. Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. Ther Adv Psychopharmacol. 2022;12:204512532210965.

Article  Google Scholar 

Singh R, Bansal Y, Medhi B, Kuhad A. Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol. 2019;844:231–40.

Article  CAS